Skip to main content
. Author manuscript; available in PMC: 2017 Mar 29.
Published in final edited form as: Gynecol Oncol. 2016 Sep 8;143(2):379–388. doi: 10.1016/j.ygyno.2016.08.328

Fig. 4. PARP is inhibited in all PDX models.

Fig. 4

A. Three in-vivo tumor replicates of treated models and controls were harvested at the end of treatment (day 28), pooled, and subjected immunoblotting of the indicated antigens. Formation of pADPr is inhibited in niraparib treated tumors. Absence of PARP1 protein is seen in model PH039 treated with niraparib. Arrow indicates expected location of 89 kDa caspase-generated PARP1 fragment if it were present. B. Lysates containing 50 μg of protein from one or two separate aliquots of the indicated PDX were subjected to SDS-PAGE and blotted with antibodies to the indicated antigen. PE01 and PE04 cells, which are known to express all of these proteins, were included as positive controls. HSP90β served as a loading control. * indicates nonspecific band. C. Parental PEO1 cells (open circles) or Artemis−/− PEO1 cells derived as described in the Materials and methods (closed circles) were plated (750 cells/plate) and treated beginning 18 h later with diluent (0.1% DMSO) or the indicated concentration of niraparib. Error bars, ±SEM from triplicate aliquots.